Join Growin Stock Community!

Grace therapeutics, inc.GRCE.US Overview

US StockHealthcare
(No presentation for GRCE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GRCE AI Insights

GRCE Overall Performance

GRCE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GRCE Recent Performance

-4.20%

Grace therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GRCE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GRCE Key Information

GRCE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GRCE Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Price of GRCE

GRCE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GRCE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.42
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.99
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.42
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.99
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GRCE's latest earnings report released?

    The most recent financial report for Grace therapeutics, inc. (GRCE) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GRCE's short-term business performance and financial health. For the latest updates on GRCE's earnings releases, visit this page regularly.

  • How much cash does GRCE have?

    At the end of the period, Grace therapeutics, inc. (GRCE) held Total Cash and Cash Equivalents of 18.67M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GRCE's EPS continuing to grow?

    According to the past four quarterly reports, Grace therapeutics, inc. (GRCE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GRCE?

    Grace therapeutics, inc. (GRCE)'s Free Cash Flow (FCF) for the period is -2.23M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 45.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GRCE?

    The latest valuation data shows Grace therapeutics, inc. (GRCE) has a Price-To-Earnings (PE) ratio of -9.14 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.